Full Press Release Details
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9.
REGN
U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9
Key Takeaway: U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9